Impure policies: controversy in HIV prevention and the making of evidence

References

• Aarden, E. 2016. “Constitutions of Justice in Genetic Medicine: Distributing Diagnostics for Familial Hypercholesterolemia in Three European Countries.” Critical Policy Studies 10: 216–234. doi:10.1080/19460171.2015.1024704.
   Web of Science ®Google Scholar
• Anderson, P. L., D. V. Glidden, A. Liu, S. Buchbinder, J. R. Lama, J. V. Guanira, V. McMahan, et al. 2012. “Emtricitabine-tenofovir Concentrations and Pre-exposure Prophylaxis Efficacy in Men Who Have Sex with Men.”Science Translational Medicine 4. doi:10.1126/scitranslmed.3004006.
   Web of Science ®Google Scholar
• Cairns, G. P., K. Race, and P. Goicochea. 2016. “PrEP: Controversy, Agency, and Ownership.” Journal of the International AIDS Society 19: 21120. doi:10.7448/IAS.19.7.21120.
   PubMed Web of Science ®Google Scholar
• Cambiano, V., A. Miners, D. Dunn, S. McCormack, K. J. Ong, O. N. Gill, A. Nardone, et al. 2018. “Cost-effectiveness of Pre-exposure Prophylaxis for HIV Prevention in Men Who Have Sex with Men in the UK: A Modeling Study and Health Economic Evaluation”. The Lancet Infectious Diseases 18: 85–94. doi:10.1016/S1473-3099(17)30540-6.
   PubMed Web of Science ®Google Scholar
• Daemmrich, A. 2003. “Invisible Monuments and the Costs of Pharmaceutical Regulation: Twenty-five Years of Drug Lag Debate.” Pharmacy in History 45: 3–17.
   PubMedGoogle Scholar
• Daemmrich, A., and G. Krucken. 2000. “Risk versus Risk: Decision-making Dilemmas of Drug Regulation in the United States and Germany.” Science as Culture 9: 505–534. doi:10.1080/713695270.
   PubMedGoogle Scholar
• Davies., O., A. Ustianowski, J. Fox. 2016. “Pre-exposure Prophylaxis for HIV Prevention: Why, What, Who and How”. Infectious Diseases and Therapy 5: 407–416. doi:10.1007/s40121-016-0128-8.
   PubMed Web of Science ®Google Scholar
• Desai, M., N. Field, R. Grant, S. McCormack. 2017. “State of the Art Review: Recent Advances in PrEP for HIV”. BMJ (clinical Research Ed.) 359: j5011. doi:10.1136/bmj.j5011.
   PubMedGoogle Scholar
• Engebretsen, E., K. Heggen, S. Wieringa, and T. Greenhalgh. 2016. “Uncertainty and Objectivity in Clinical Decision Making: A Clinical Case in Emergency Medicine.” Med Health Care Philos Published Online First. doi:10.1007/s11019-016-9714-5.
   Google Scholar
• Epstein, S. 1996. Impure Science: AIDS, Activism, and the Politics of Knowledge.Berkeley: Univ of California Press.
   Google Scholar
• Gardener, J., and A. Webster. 2016. “The Social Management of Biomedical Novelty: Facilitating Translation in Regenerative Medicine.” Social Science & Medicine 156: 90–97. doi:10.1016/j.socscimed.2016.03.025.
   PubMed Web of Science ®Google Scholar
• Grant, R. M., P. L. Anderson, V. McMahan, A. Liu, K. R. Amico, M. Mehrotra, S. Hosek, et al. 2014. “Uptake of Pre-exposure Prophylaxis, Sexual Practices, and HIV Incidence in Men and Transgender Women Who Have Sex with Men: A Cohort Study.” The Lancet Infectious Diseases 14 (9): 820–829. doi:10.1016/S1473-3099(14)70847-3.
   PubMed Web of Science ®Google Scholar
• Grant, R. M., and K. A. Koester. 2016. “What People Want from Sex and Preexposure Prophylaxis.” Current Opinion in HIV and AIDS 11: 3–9. doi:10.1097/COH.0000000000000216.
   PubMed Web of Science ®Google Scholar
• Grant, R. M., J. R. Lama, P. L. Anderson, V. McMahan, A. Y. Liu, L. Vargas, P. Goicochea, et al. 2010. “Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.” New England Journal of Medicine 363 (27): 2587–2599. doi:10.1056/NEJMoa1011205.
   PubMed Web of Science ®Google Scholar
• Greenhalgh, T., and J. Russell. 2006. “Reframing Evidence Synthesis as Rhetorical Action in the Policy-making Drama.” Healthcare Policy 1 (2): 34.
   PubMedGoogle Scholar
• Greenhalgh, T., and J. Russell. 2009. “Evidence-based Policymaking: A Critique.” Perspectives in Biology and Medicine 52 (2): 304–318. doi:10.1353/pbm.0.0085.
   PubMed Web of Science ®Google Scholar
• Hawkes, N. 2016. “NHS Can Fund HIV Prevention Drug, Court Rules.”BMJ2016, 355: i6082.
   Google Scholar
• Iacobucci, G. 2016. “HIV Charity Criticises NHS England Over” Homophobic” PrEP Statement.” BMJ: British Medical Journal 354: i4347. (Online).
   Web of Science ®Google Scholar
• Iacobucci, G. 2017. “Trial Will Make HIV Prevention Drugs Available on NHS from September.”BMJ, 358: j3758.
   Google Scholar
• Jansen, M. P. M., N. Tromp, and R. Baltussen. 2016. “PrEP: Why We are Waiting.” Lancet HIV 3 (1): E11–E12. doi:10.1016/S2352-3018(15)00250-7.
   PubMed Web of Science ®Google Scholar
• Jasanoff, S., ed. 2004. States of Knowledge: The Co-production of Science and the Social Order. London: Routledge.
   Google Scholar
• Jasanoff, S. 2009. The Fifth Branch: Science Advisers as Policymakers. Cambridge, MA: Harvard University Press.
   Google Scholar
• Jasanoff, S. 1987. “Contested Boundaries in Policy-relevant Science.” Social Studies of Science 17 (2): 195–230. doi:10.1177/030631287017002001.
   Web of Science ®Google Scholar
• Lancet HIV. 2016. “NHS England Should Reconsider PrEP Decision.” The Lancet. HIV 3 (5): e191. doi:10.1016/S2352-3018(16)30020-0.
   PubMed Web of Science ®Google Scholar
• Lancet HIV. 2016b. “Time for NHS England to Accept Responsibility for PrEP.” The Lancet. HIV 3: e397. doi:10.1016/S2352-3018(16)30117-5.
   PubMed Web of Science ®Google Scholar
• Lancet HIV. 2017. “Better Late than Never: PrEP in England.” The Lancet. HIV 4 (1): e1. doi:10.1016/S2352-3018(16)30208-9.
   Google Scholar
• Latour, B. 1987. Science in Action: How to Follow Scientists and Engineers through Society. Cambridge, MA: Harvard university press.
   Google Scholar
• Latour, B., and S. Woolgar. 2013. Laboratory Life: The Construction of Scientific Facts. Princeton, NJ: Princeton University Press.
   Google Scholar
• Lodi, S., A. Phillips, R. Logan, A. Olson, D. Costagliola, S. Abgrall, A. van Sighem, et al., Lancet HIV. 2015. “PrEP: Why are We Waiting?” The Lancet. HIV 2 (10): e401. doi:10.1016/S2352-3018(15)00108-3.
   PubMed Web of Science ®Google Scholar
• McCormack, S., Fidler, S., Waters, L., Azad, Y., Barber, T., Cairns, G., Cambiano, V., Clutterbuck, D., Desai, M., Dunn, D. 2016. London, BHIVA–BASHH Position Statement on PrEP in the UK. Second update May.
   Google Scholar
• Nwokolo, N., and G. Whitlock. 2017. “Not Just PrEP: Other Reasons for London’s HIV Decline.” The Lancet HIV 4 (4): e153. doi:10.1016/S2352-3018(16)30208-9.
   PubMed Web of Science ®Google Scholar
• Paparini, S., and T. Rhodes. 2016. “The Biopolitics of Engagement and the HIV Cascade of Care: A Synthesis of the Literature on Patient Citizenship and Antiretroviral Therapy.” Critical Public Health 26 (5): 501–517. doi:10.1080/09581596.2016.1140127.
   Web of Science ®Google Scholar
• Prior, L. 2001. “Rationing through Risk Assessment in Clinical Genetics: All Categories Have Wheels.” Sociology of Health & Illness 23: 570–593. doi:10.1111/shil.2001.23.issue-5.
   Web of Science ®Google Scholar
• Rhodes, T., Lancaster, K., Harris, M., Treloar, C. 2018. “Evidence-making Controversies: The Case of Hepatitis C Treatment and the Promise of Viral Elimination.” Critical Public Health, 29(3): 260–273.
   Web of Science ®Google Scholar
• Rhodes, T., E. F. Closson, S. Paparini, A. Guise, S. Strathdee. 2016. “Towards “evidence-Making Intervention” Approaches in the Social Science of Implementation Science: The Making of Methadone in East Africa”. International Journal of Drug Policy 30: 17–26. doi:10.1016/j.drugpo.2016.01.002.
   PubMed Web of Science ®Google Scholar
• Roberta., E. 2016. “Controversy Surrounds NHS Delays over Commissioning PrEP.” Prescriber 27 (8): 12–13. doi:10.1002/psb.1486.
   Google Scholar
• Russell, J., T. Greenhalgh, E. Byrne, J. Mcdonnell. 2008. “Recognizing Rhetoric in Health Care Policy Analysis.” Journal of Health Services Research & Policy 13 (1): 40–46. doi:10.1258/jhsrp.2007.006029.
   PubMed Web of Science ®Google Scholar
• Russell, J., and T. Greenhalgh. 2011. “Policymaking through a Rhetorical Lens.” Evidence, Policy, and Practice: Critical Perspectives in Health and Social Care 49–60. Bristol Policy Press
   Google Scholar
• Serrant, L. 2016. “Sex, PrEP and the Moral Backlash: A High Court Decision on the Funding of A Drug that Prevents HIV Shows 1980s Prejudice Lingers On.” Nursing Standard 30 (50): 27. doi:10.7748/ns.30.35.32.s38.
   PubMedGoogle Scholar
• Steven., E. 1995. “The Construction of Lay Expertise: AIDS Activism and the Forging of Credibility in the Reform of Clinical Trials.” Science, Technology, & Human Values 20: 408–437. doi:10.1177/016224399502000402.
   PubMed Web of Science ®Google Scholar
• Suraratdecha, C., R. M. Stuart, C. Manopaiboon, D. Green, C. Lertpiriyasuwat, D. P. Wilson, P. Pavaputanon, et al. 2018. “Cost and Cost‐effectiveness Analysis of Pre‐exposure Prophylaxis among Men Who Have Sex with Men in Two Hospitals in Thailand”. Journal of the International AIDS Society 21: e25129. doi:10.1002/jia2.25129.
   PubMed Web of Science ®Google Scholar
• UNAIDS. 2018. Miles to Go—Closing Gaps, Breaking Barriers, Righting Injustices. UNAIDS, Geneva
   Google Scholar
• Van De Vijver, D. A. M. C., A.-K. Richter, C. A. B. Boucher, B. Gunsenheimer-Bartmeyer, C. Kollan, B. E. Nichols, C. D. Spinner, et al. 2019. “Cost-effectiveness and Budget Effect of Pre-exposure Prophylaxis for HIV-1 Prevention in Germany from 2018 to 2058.”Eurosurveillance 24. doi:10.2807/1560-7917.ES.2019.24.7.1800398.
   Web of Science ®Google Scholar
• WHO. July 2012. Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects.
   Google Scholar
• WHO. 2016. Action Plan for Sexual and Reproductive Health. Towards achieving the 2030 Agenda for Sustainable Development in Europe - leaving no one behind.
   Google Scholar